Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The pharmacophore of the human C5a anaphylatoxin
- M. Toth, L. Huwyler, +7 authors N. Galakatos
- Biology, Medicine
- Protein science : a publication of the Protein…
- 1 August 1994
We have determined which amino acids contribute to the pharmacophore of human C5a, a potent inflammatory mediator. A systematic mutational analysis of this 74‐amino acid protein was performed and the… Expand
Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
Novel recombinant human C5a receptor antagonists were discovered through modification of the C terminus of C5a. The C5a1-71T1M,C27S,Q71C monomer, (C5aRAM; CGS 27913), was a pure and potent functional… Expand
Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
Purpose: Zoledronic acid (ZOL) given every 3 to 4 weeks can reduce skeletal-related events (SRE) in patients with bone lesions from multiple myeloma. This study evaluated efficacy and safety of… Expand
The biochemical and pharmacological activity of 9-benzyl-9-deazaguanine, a potent purine nucleoside phosphorylase (PNP) inhibitor
Patients deficient in purine nucleoside phosphorylase (PNP), show marked impairment in T-cell immune function but normal to elevated B-cell function , The mechanism for this deficiency involves a… Expand
Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial.
- B. Bartlett, S. Tyring, +4 authors E. Berber
- Journal of clinical virology : the official…
- 1 October 2008
BACKGROUND Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and… Expand
Erratum to: Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes : The RELIEF trial LJ. Clin. Virol. 43
This information is current as Neutrophil Functions In Vitro and In Vivo Novel C 5 a Receptor Antagonists Regulate